Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Astellas and Ambit work on FLT3 kinase inhibitors; deal ending

Executive Summary

Ambit Biosciences (cancer and inflammatory disease therapies) has announced that it will jointly develop its lead compound AC220 for acute myeloid leukemia, plus other FLT3 kinase inhibitors, with Japan's Astellas Pharma.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Co-Promotion
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register